DelveInsight’s, “Refractory Multiple Myeloma Pipeline Insight 2025” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Refractory Multiple Myeloma pipeline landscape. It covers the Refractory Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Refractory Multiple Myeloma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Refractory Multiple Myeloma Pipeline Report to explore emerging therapies, key Refractory Multiple Myeloma Companies, and future Refractory Multiple Myeloma treatment landscapes @ Refractory Multiple Myeloma Pipeline Outlook Report

Key Takeaways from the Refractory Multiple Myeloma Pipeline Report

• In April 2025, Ontario Clinical Oncology Group announced a phase II study of single agent elranatamab in patients with relapsed and/or refractory multiple myeloma (MM) who have previously received at least three classes of therapeutic agents and are refractory to the last line of treatment. The primary objective of this study is to improve the tolerability and safety of elranatamab in patients with relapsed and/or refractory multiple myeloma by evaluating an outpatient and intermittent dosing strategy.
• DelveInsight’s Refractory Multiple Myeloma pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Refractory Multiple Myeloma treatment.
• The leading Refractory Multiple Myeloma Companies such as MorphoSys, Janssen Research & Development, LLC, Rapa Therapeutics, Novartis, AbbVie, MiNK Therapeutics, Amgen, Gracell Biopharmaceuticals, Inc., Zhejiang ACEA Pharmaceutical Co. Ltd., Allogene Therapeutics, Beijing InnoCare Pharma Tech Co., Ltd., Takeda, Novartis Pharmaceuticals and others.
• Promising Refractory Multiple Myeloma Pipleline Therapies such as Isatuximab SC-OBDS, Montelukast, Dexamethasone, Elotuzumab, Iberdomide, Selinexor, Bortezomib, Elranatamab,Carfilzomib, REGN5459 and others.

Stay ahead with the most recent pipeline outlook for Refractory Multiple Myeloma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Refractory Multiple Myeloma Treatment Drugs

Refractory Multiple Myeloma Emerging Drugs Profile

• Felzartamab: MorphoSys

Felzartamab is an investigational human monoclonal antibody developed using MorphoSys’ HuCAL® antibody technology. The antibody targets against CD38 present on the surface of multiple myeloma cells. The drug candidate uses antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) for tumor cell killing. Currently it is in Phase III stage of clinical trial evaluation to treat Refractory Multiple Myeloma.

• RAPA-201: Rapa Therapeutics

RAPA-201 It is a type of autologous cell therapy. The drug candidate is gene transference, T lymphocyte replacements and work on the same mechanism of action. Currently the drug is being evaluated in Phase II for the treatment of Refractory Multiple Myeloma.

• PHE885: Novartis

PHE885 is an autologous, fully human, BCMA-directed CAR T-cell therapy being developed by Novartis for the treatment of refractory multiple myeloma. It is administered through intravenous route. The therapeutic candidate consists of autologous T cells that are genetically modified to express chimeric antigen receptor that targets BCMA (B-cell maturation antigen). Currently it is in Phase II stage of clinical trials.

• ABBV 453: AbbVie

ABBV-453 is an investigational drug candidate being developed for the treatment of relapsed or refractory multiple myeloma. It is administered through oral route as tablet formulation. It acts by targeting B-cell lymphoma 2 (BCL-2) protein. Currently the drug is in Phase I stage of clinical trials.

The Refractory Multiple Myeloma Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Refractory Multiple Myeloma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Refractory Multiple Myeloma treatment.
• Refractory Multiple Myeloma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Refractory Multiple Myeloma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Refractory Multiple Myeloma market.

Explore groundbreaking therapies and clinical trials in the Refractory Multiple Myeloma Pipeline. Access DelveInsight’s detailed report now! @ New Refractory Multiple Myeloma Drugs

Refractory Multiple Myeloma Companies

MorphoSys, Janssen Research & Development, LLC, Rapa Therapeutics, Novartis, AbbVie, MiNK Therapeutics, Amgen, Gracell Biopharmaceuticals, Inc., Zhejiang ACEA Pharmaceutical Co. Ltd., Allogene Therapeutics, Beijing InnoCare Pharma Tech Co., Ltd., Takeda, Novartis Pharmaceuticals and others.

Refractory Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Refractory Multiple Myeloma Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Unveil the future of Refractory Multiple Myeloma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Refractory Multiple Myeloma Market Drivers and Barriers

Scope of the Refractory Multiple Myeloma Pipeline Report

• Coverage- Global
• Refractory Multiple Myeloma Companies- MorphoSys, Janssen Research & Development, LLC, Rapa Therapeutics, Novartis, AbbVie, MiNK Therapeutics, Amgen, Gracell Biopharmaceuticals, Inc., Zhejiang ACEA Pharmaceutical Co. Ltd., Allogene Therapeutics, Beijing InnoCare Pharma Tech Co., Ltd., Takeda, Novartis Pharmaceuticals and others.
• Refractory Multiple Myeloma Pipleline Therapies- Isatuximab SC-OBDS, Montelukast, Dexamethasone, Elotuzumab, Iberdomide, Selinexor, Bortezomib, Elranatamab,Carfilzomib, REGN5459 and others.
• Refractory Multiple Myeloma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Refractory Multiple Myeloma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Refractory Multiple Myeloma Drug development? Find out in DelveInsight’s exclusive Refractory Multiple Myeloma Pipeline Report—access it now! @ Refractory Multiple Myeloma Emerging Drugs and Major Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Multiple Myeloma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Comparative Analysis
8. Felzartamab: MorphoSys
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. RAPA-201: Rapa Therapeutics
12. Early Stage Products (Phase I )
13. Comparative Analysis
14. ABBV 453: AbbVie
15. Inactive Products
16. Refractory Multiple Myeloma Key Companies
17. Refractory Multiple Myeloma Key Products
18. Refractory Multiple Myeloma- Unmet Needs
19. Refractory Multiple Myeloma- Market Drivers and Barriers
20. Refractory Multiple Myeloma- Future Perspectives and Conclusion
21. Refractory Multiple Myeloma Analyst Views
22. Refractory Multiple Myeloma Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/refractory-multiple-myeloma-pipeline-insight